ENDV OTC
Endonovo Therapeutics, Inc.
1W: +0.0%
1M: -50.0%
3M: -50.0%
YTD: -50.0%
1Y: -50.0%
3Y: -99.6%
5Y: -99.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
$0
+100.0% ▲
Operating Income
-$946K
+39.4% ▲
Net Income
-$2M
+22.2% ▲
EPS (Diluted)
$-0.00
+76.5% ▲
EBITDA
-$946K
-0.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $73K | $135K | $140K | $10K | $0 |
| YoY Growth | -55.9% | +85.2% | +3.6% | -92.8% | -100.0% |
| Cost of Revenue | $15K | $10K | $655K | $625K | $0 |
| Gross Profit | $58K | $125K | -$515K | -$615K | $0 |
| Gross Margin | 79.5% | 92.6% | -366.9% | -6125.6% | — |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2M | $3M | $2M | $945K | $946K |
| Operating Expenses | $2M | $3M | $2M | $945K | $946K |
| Operating Income | -$2M | -$3M | -$3M | -$2M | -$946K |
| Operating Margin | -3045.7% | -2411.7% | -2081.7% | -15532.5% | — |
| Interest Expense | $942K | $1M | $1M | $1M | $1M |
| Income Before Tax | -$3M | -$18M | $7M | -$3M | -$2M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$3M | -$18M | $7M | -$3M | -$2M |
| Net Margin | -4247.2% | -13649.2% | 4937.6% | -27853.2% | — |
| EPS (Diluted) | $-0.05 | $-0.13 | $0.01 | $-0.01 | $-0.00 |
| EBITDA | -$2M | -$17M | $9M | -$941K | -$946K |
| Shares Outstanding | 60M | 139M | 1.35B | 544M | 1.81B |